Koneksa has built a software suite that ingests sensor data from devices — from portable spirometers to iPhones and Apple Watches — and uses algorithms to extract clinically useful signals and organize them for drug companies and trial sites. The company aims to convert analog clinical scales into digital, more granular measures (for example quantifying Parkinson’s tremors via phone sensors) and has run studies showing at-home measures can correlate with clinic tests. Koneksa has supported clinical trials at over 700 sites and published internal studies such as a 12-patient asthma spirometer comparison and a 66-patient head-and-neck cancer activity study. Its current focus is clinical validation of digital biomarkers to meet the evidentiary standards of leading drug companies and to enable regulatory use. Planned product initiatives include Koneksa-owned and collaborator studies to build evidence and a "self-service" platform that lets partners combine and license integrated device-data dashboards. Financially, the company had previously raised roughly $4M in seed/Series A and $16M in a Series B and is announcing a $45M Series C to fund validation and the platform launch. Koneksa develops a patient-centric digital biomarker platform for drug development, delivered via a SaaS platform and mobile application. The platform integrates wearables, sensors and other patient-facing technologies to capture, monitor and analyze patient-generated data collected at home and remotely. Koneksa provides its own mobile assessments and can work with a variety of existing wearable sensors to enable a broad array of data inputs. The company has partnered with pharmaceutical and biotech firms to develop and implement digital biomarkers across therapeutic areas including neuroscience, respiratory, rare diseases and oncology. Launched in 2015 and led by CEO Chris Benko, Koneksa recently closed a $16M Series B to support R&D, validation of digital endpoints, platform advancement, strategic partnerships and geographic expansion.

Total raised

$61M

Funding rounds

2

Latest round

Series C

Latest activity

Feb 2022